

July 1, 2017

The Listing Department,  
BSE Limited (BSE)  
Phiroze Jeejeebhoy Towers, Dalal Street,  
Mumbai- 400 001

**Scrip ID-540025**

The Listing Department,  
National Stock Exchange of India Ltd. (NSE)  
Exchange Plaza, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai- 400 051

**Scrip Code-ADVENZYMES**

Dear Sir,

**Subject: Outcome of Board Meeting held on July 1, 2017**

**Ref: ISIN: INE837H01020**

We hereby inform that the Board of Directors in its Meeting held on July 1, 2017 (commenced at 9.30 a.m. and concluded at 11.00 a.m.) has inter alia, approved the following:

1. 28th Annual General Meeting (AGM) of the Members of Advanced Enzyme Technologies Limited will be held on Wednesday, September 06, 2017, at 11.30 a.m. at Shehnaï Banquet Hall, Shahid Mangal Pandey Road, Louiswadi, Opposite Louis Wadi Police Chowki, Thane (West) – 400601.
2. The final dividend, if approved / declared by the Members at AGM, will be paid on and from the second (2<sup>nd</sup>) day from the date of AGM i.e. September 08, 2017 and not later than September 30, 2017 (Kindly note that the recommendation of final dividend was approved by the Board of Directors of the Company on May 27, 2017 and was intimated to BSE and NSE vide our letter dated May 27, 2017)
3. The Register of Members and Share Transfer Books of the Company ('Book Closure') shall remain closed from August 31, 2017 (Thursday) to September 06, 2017 (Wednesday) (both the days inclusive) for the purpose of 28<sup>th</sup> AGM and ascertaining the Members who shall be entitled to receive the final dividend, if approved at the 28<sup>th</sup> AGM.
4. Incorporation of wholly owned subsidiary in Netherlands and investment in relation thereto. It is expected to be completed by end of July 2017.



The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015 in relation to the Incorporation of wholly owned subsidiary in Netherlands, are as follows:

| Sr. No. | Particulars   | Status / Remarks  |
|---------|---|---|
| a)      | Name of the target entity, details in brief such as size, turnover etc.;  | Proposed name of the Subsidiary to be incorporated: Advanced Enzymes Europe B.V.<br><br>Presently not applicable as it would be a newly incorporated wholly owned subsidiary. |
| b)      | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?<br><br>If yes, nature of interest and details thereof and whether the same is done at "arm's length" | Not Applicable  |
| c)      | Industry to which the entity being acquired belongs   | Special Purpose Vehicle   |
| d)      | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)  | For expansion of business of the Company in European market.  |
| e)      | Brief details of any governmental or regulatory approvals required for the acquisition  | Approval of authorities in Netherlands and Overseas Direct Investment (ODI) related compliances with Reserve Bank of India (RBI).   |
| f)      | Time period for completion of the acquisition   | The Incorporation is expected to be completed by end of July 2017   |
| g)      | Nature of consideration   | Cash  |
| h)      | Cost of acquisition or the price at which the shares are acquired   | The investment of the Company will be in equity shares of Euro 1 each (at par value) for an aggregate amount not exceeding Euro 2 Million.                                    |
| i)      | Percentage of shareholding / control  | 100%  |

|    |   |   |
|----|---|---|
|    | acquired and / or number of shares acquired   |   |
| j) | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); | Not Applicable as it will be a newly incorporated wholly owned subsidiary of the Company. |

This is for your information and for public at large.

Thanking you,

Yours Faithfully,

For Advanced Enzyme Technologies Limited



**Sanjay Basantani**

**Company Secretary and Head – Legal**